{"nctId":"NCT02385097","briefTitle":"Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block","startDateStruct":{"date":"2015-04","type":"ACTUAL"},"conditions":["Axillary Nerve Block"],"count":211,"armGroups":[{"label":"Chloroprocaine HCl 2% (20 mg/mL)","type":"EXPERIMENTAL","interventionNames":["Drug: Chloroprocaine HCl 2%"]},{"label":"Ropivacaine 0.75% (7.5 mg/mL)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ropivacaine 0.75%"]}],"interventions":[{"name":"Chloroprocaine HCl 2%","otherNames":["Ampres"]},{"name":"Ropivacaine 0.75%","otherNames":["Naropin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Sex and surgery: male and female patients scheduled for short duration (\\< 60 min) distal upper limb surgery under axillary nerve block anaesthesia\n2. Age: ≥ 18 years old\n3. Body Mass Index (BMI): 18 - 32 kg/m2 inclusive\n4. ASA physical status: I-III\n5. Informed consent: signed written informed consent before inclusion in the study\n6. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study\n\nExclusion Criteria:\n\n1. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study. Contraindications to peripheral nerve block anaesthesia. History of neuromuscular diseases to the upper extremities\n2. Axillary status: Axillary local infections, surgical scarring and pathological lymph node enlargement\n3. ASA physical status: IV-V\n4. Further anaesthesia: Patients anticipated to be requiring further anaesthesia (general or local anaesthesia)\n5. Chronic pain syndromes: Patients with chronic pain syndromes (taking opioids, antidepressants, anticonvulsant agents)\n6. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations ingredients; ascertained or presumptive hypersensitivity to the amide and ester-type anaesthetics\n7. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study; ascertained psychiatric diseases, sepsis, blood coagulation disorders, insulin dependent diabetes mellitus, terminal kidney failure\n8. Medications: Medication known to interfere with the extent of regional blocks (see chloroprocaine and ropivacaine SmPCs) for 2 weeks before the start of the study. Hormonal contraceptives for females will be allowed\n9. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study, calculated from the first day of the month following the last visit of the previous study\n10. Drug, alcohol: history of drug or alcohol abuse\n11. Pregnancy: missing or positive pregnancy test at screening, pregnant or lactating women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Successful Block for Distal Upper Limb Surgeries","description":"Percentage of patients with a successful block for distal upper limb surgeries, without any supplementation in the first 45 min, calculated from the time of readiness for surgery (complete sensory block).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)","description":"Time period from completion of the final perineural injection (time 0 h) to achievement of sensory block in the 4 nerve territories","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of Motor Block","description":"Time period from completion of the final perineural injection (time 0 h) to achievement of motor block","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Regression of Sensory Block","description":"Will be deemed to have occurred when cold sensation and sensitive perception have returned (if assessable) in any nerve territory","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"451","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Regression of Motor Block","description":"Will be deemed to have occurred when motor score is ≥ 3 (Modified Bromage scale) in any nerve territory (Modified Bromage scale: 0-No movement in relevant muscle group,1-Flicker of movement in relevant muscle group,2-Ability to move relevant muscle group against gravity but inability to move against resistance,3-Reduced power but ability to move muscle group against resistance,4-Full power in relevant muscle group)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"415","spread":null}]}]}]},{"type":"SECONDARY","title":"Partecipants Received Rescue Anaesthesia or Rescue Analgesia","description":"partecipants received rescue anaesthesia or rescue analgesia from completion of the final perineural injection (time 0 hour) to administration of first rescue anaesthesia or analgesia (supplementation)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Received Post-operative Analgesia","description":"Number of subjects who received the first post-operative analgesia","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Eligibility for Home Discharge","description":"Time from completion of the final perineural injection (time 0 h) to the time when the criteria for discharge are met, even if, according to the hospital procedures, the patient is discharged from the hospital at a later time","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"355.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"Number of Participants with Treatment-emergent Adverse Events (TEAEs) occurring or worsening after the first dose of IMP","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Neurological Symptoms","description":"Number of patients with Neurological Symptoms (e.g. paraesthesia, motor function problems and pain at the injection site)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Heart Rate","description":"The following normal ranges Heart Rate parameters will be used:\n\n50-90 beats/min","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":"12"},{"groupId":"OG001","value":"73.6","spread":"12.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":"10.8"},{"groupId":"OG001","value":"71.6","spread":"12.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.5","spread":"11.5"},{"groupId":"OG001","value":"73","spread":"12.3"}]}]}]},{"type":"SECONDARY","title":"Blood Pressure","description":"The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used:\n\nSystolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":"20.5"},{"groupId":"OG001","value":"136.2","spread":"18.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136.6","spread":"18.9"},{"groupId":"OG001","value":"138","spread":"19.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130.5","spread":"17.8"},{"groupId":"OG001","value":"130.1","spread":"17.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":"11.4"},{"groupId":"OG001","value":"80.5","spread":"9.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.2","spread":"10.7"},{"groupId":"OG001","value":"80.1","spread":"10.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":"11.1"},{"groupId":"OG001","value":"75.4","spread":"9.8"}]}]}]},{"type":"SECONDARY","title":"SpO2","description":"The following normal ranges SpO2 parameters will be used:\n\nPeripheral Oxygen Saturation: ≥ 95%","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.05","spread":"1.51"},{"groupId":"OG001","value":"97.36","spread":"1.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.47","spread":"1.52"},{"groupId":"OG001","value":"97.61","spread":"1.33"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Normal Electrocardiogram (ECG) Parameters","description":"Number of Participants with Normal Electrocardiogram (ECG) Parameters. The following normal ranges ECG parameters will be used:\n\nHeart Rate: 50-90 beats/min PR Interval: 100-220 msec QRS Duration: ≤ 120 msec QT Interval: ≤ 500 msec","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":106},"commonTop":["Procedural pain","Hypoaestesia","Paraestesia","burning sensation","pain in extremity"]}}}